Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells

Authors: Fumihiko Matsuzawa, Hirofumi Kamachi, Tatsuzo Mizukami, Takahiro Einama, Futoshi Kawamata, Yuki Fujii, Moto Fukai, Nozomi Kobayashi, Yutaka Hatanaka, Akinobu Taketomi

Source: BMC Cancer, Vol 21, Iss 1, Pp 1-16 (2021)

Subject Terms: Amatuximab, Mesothelin, Peritoneal metastasis, Cancer stem cell, Pancreatic cancer, pMET, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/59a5ff8880764bcdb8c4c420ec5d8690

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Morphotek Inc announces initiation of amatuximab study in first-line, unresectable, malignant pleural mesothelioma patients.

Source: Chemical Business NewsBase (UK), November 18, 2015, 1pp

Orphan designation: Amatuximab for the treatment of malignant mesothelioma, 16 Jan 2014, Positive (EU/3/13/1222).

Source: Chemical Business NewsBase (UK), October 12, 2018, 1pp